Cholecystokinin receptor type A · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Cholecystokinin receptor type A shows late clinical disease relevance led by irritable bowel syndrome. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P32238. Start with irritable bowel syndrome, then reuse UniProt P32238 as the stable protein anchor across project notes and exports.
Start with irritable bowel syndrome, then reuse UniProt P32238 as the stable protein anchor across project notes and exports.
Cholecystokinin receptor type A shows late clinical disease relevance led by irritable bowel syndrome. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with irritable bowel syndrome because it currently carries late clinical support. Linked drugs include DEXLOXIGLUMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCholecystokinin receptor type A
Review this target as Cholecystokinin receptor type A, mapped to UniProt P32238. Sequence length is 428 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cholecystokinin receptor type A as ChEMBL target CHEMBL1901, mapped to UniProt P32238. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Cholecystokinin receptor type A is the right protein anchor across sources, using UniProt P32238 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why irritable bowel syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Cholecystokinin receptor type A |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P32238 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Cholecystokinin receptor type A |
| UniProt Accession | P32238 |
| Component Type | Protein |
| Sequence Length | 428 aa |
Cholecystokinin receptor type A
Review this target as Cholecystokinin receptor type A, mapped to UniProt P32238. Sequence length is 428 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Cholecystokinin receptor type A shows late clinical disease relevance led by irritable bowel syndrome. 2 more disease programs remain visible in the same review block.
Start review with irritable bowel syndrome because it currently carries late clinical support. Linked drugs include DEXLOXIGLUMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1269257 | 11.0 | EC50 | 0.01 | Preclinical |
| CHEMBL504114 | 11.0 | IC50 | 0.01 | Preclinical |
| CHEMBL156605 | 10.85 | EC50 | 0.014 | Preclinical |
| CHEMBL509464 | 10.8 | IC50 | 0.016 | Preclinical |
| CHEMBL450105 | 10.74 | IC50 | 0.018 | Preclinical |
| CHEMBL105775 | 10.7 | EC50 | 0.02 | Preclinical |
| CHEMBL9506 | 10.63 | Ki | 0.02344 | Clinical |
| CHEMBL423907 | 10.6 | EC50 | 0.02512 | Preclinical |
| CHEMBL505225 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL509519 | 10.52 | IC50 | 0.03 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 153 | 189 | 7.8 |
| cell-based format | 108 | 253 | 7.2 |
| cell membrane format | 3 | 5 | 6.0 |
| tissue-based format | 3 | 0 | — |
| assay format | 1 | 1 | 5.5 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 49 | 106 | 8.3 |
| assay format | 11 | 87 | 8.5 |
| organism-based format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell membrane format | 1 | 3 | 5.2 |